Drug Profile
Research programme: metabolic disorder therapeutics - EastGate Biotech
Alternative Names: Intraoral insulin - EastGate BiotechLatest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator EastGate Acquisitions
- Developer EastGate Biotech
- Class Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus; Metabolic disorders; Obesity
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Diabetes mellitus in USA (PO)
- 25 Apr 2023 Discontinued for Metabolic disorders in USA (unspecified route)
- 25 Apr 2023 Discontinued for Obesity in USA (unspecified route)